SCHEMBL27088159

SCHEMBL27088159

CC1(C)Oc2cnc(Cl)nc2NC1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 5/20 0.37
SYK P43405 4/20 0.35
TYRO3 Q06418 2/20 0.35
BMPR1B O00238 1/20 0.35
CDC7 O00311 1/20 0.35
PIK3CD O00329 1/20 0.35
PLK4 O00444 1/20 0.35
STK25 O00506 1/20 0.35
CIT O14578 1/20 0.35
RIOK3 O14730 1/20 0.35
CHEK1 O14757 1/20 0.35
IKBKB O14920 1/20 0.35
AURKA O14965 1/20 0.35
GAK O14976 1/20 0.35
CHUK O15111 1/20 0.35
MUSK O15146 1/20 0.35
EPHB6 O15197 1/20 0.35
MAPK13 O15264 1/20 0.35
PDPK1 O15530 1/20 0.35
DAPK3 O43293 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30033586 1.00 BRD4 (0.37) BRD4SYKTYRO3BMPR1BCDC7
SCHEMBL13425071 0.78 BRD4 (0.36) BRD4SYKTYRO3BMPR1BCDC7
Ammonia Solution, Strong SCHEMBL2517930 0.76 SYK (0.42) BRD4SYKTYRO3BMPR1BCDC7
SCHEMBL1083288 0.74 SYK (0.62) BRD4SYKTYRO3BMPR1BCDC7
SCHEMBL27088248 0.73 PARP1 (0.41) TYRO3KDRDYRK1BPDE3BPDE3A
SCHEMBL30032265 0.73 PARP1 (0.41) TYRO3KDRDYRK1BPDE3BPDE3A
SCHEMBL4146597 0.71 BRD4 (0.53) BRD4SYKTYRO3BMPR1BCDC7
SCHEMBL16606964 0.71 SYK (0.52) BRD4SYKTYRO3BMPR1BCDC7
SCHEMBL29671171 0.71 SYK (0.52) BRD4SYKTYRO3BMPR1BCDC7
SCHEMBL29036314 0.71 KDM4E (0.33) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226107-A1 UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-07-11 US disclosed
US-20240226107-A1 UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-07-11 US disclosed
EP-4321515-A1 UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR Simcere Zaiming Pharmaceutical Co., Ltd. (CN) 2024-02-14 EP disclosed
WO-2023245611-A1 SMALL MOLECULE COMPOUND WITH TTK INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND USE THEREOF 四川大学华西医院 2023-12-28 WO disclosed
CN-116462679-A Pyrazolopyrimidine derivative and application thereof in medicine 四川海思科制药有限公司 2023-07-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226107-A1 UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR USP1, USP2, USP3 BRD4 1342/4885SYK 3495/4885TYRO3 4476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.